Growth hormone output does decline with age, and that decline is real and measurable. But the specific statistics that circulate about it, muscle loss per decade, the 1990 GH trial, are mostly misquoted. Here is what the underlying studies actually found.
Peptide Research
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
Growth hormone is not secreted at a constant rate. It is released in pulses, and those pulses can be characterized by deconvolution analysis, which reconstructs the underlying secretory bursts from a series of blood samples. That kind of analysis, done in healthy men, found that age and relative adiposity are specific, independent negative determinants of the frequency and amplitude of GH secretory bursts, and of the half-life of endogenous GH.1
Two things in that finding matter more than the headline. First, age was not the only variable identified. Relative adiposity, meaning how much body fat someone carries, independently predicted lower GH secretion. Second, adiposity is modifiable in a way that chronological age is not. A person's body composition is a lever that exists before any peptide enters the conversation.
That reframes the usual story. 'GH falls because you get older' is only half the finding. The fuller finding is that GH falls with age and with adiposity, and only one of those two is something a person has any control over. Someone focused entirely on replacing declining GH pharmacologically, while ignoring the adiposity side of the equation the original study identified, is treating half the problem.
IGF-1, insulin-like growth factor 1, is the downstream signal most often used as a proxy for growth hormone activity, because it is more stable in blood than GH itself and reflects average GH exposure over time. A large multicentre study built reference intervals for IGF-1 from birth to senescence using a modern automated assay, and the resulting curve peaks during adolescence and falls steadily across adulthood from there.2
This is a normal, expected biological curve, not a disease process. IGF-1 is highest during the growth spurt of adolescence, when the body is building new tissue at its fastest lifetime rate, and it declines afterward as that growth program winds down. A lower IGF-1 at 45 than at 17 is not itself evidence of dysfunction; it is evidence of having finished growing decades earlier.
What the reference-interval data is useful for is context: it tells a clinician what a given IGF-1 value means for a person of a given age and sex, which is the only way an isolated lab result becomes interpretable. It does not, on its own, establish what level of IGF-1 an adult should be trying to restore, or that restoring a younger person's IGF-1 level produces a younger person's outcomes.
A specific statistic circulates widely online: that people lose some fixed percentage of muscle mass per decade starting at 30. The number attached to that claim varies by source and is rarely traceable to a specific study, which is itself a warning sign.
A quantitative review of sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength lays out what the actual literature supports, and the picture is more specific and more useful than a single percentage.3 Muscle mass does decline with age, but the decline in mass is modest for most of adulthood and accelerates later in life. It is not a smooth, large, linear loss beginning promptly at 30.
The more important finding in that review is the one the popular statistic leaves out entirely: strength declines faster than muscle mass does. The review distinguishes sarcopenia, the loss of muscle mass, from dynapenia, the loss of muscle strength, and finds that dynapenia outpaces sarcopenia across the aging process.3 In practical terms, a person can retain a large share of their muscle mass while still losing meaningful strength and function, because strength depends on more than tissue quantity: neuromuscular activation, motor unit recruitment, and tendon and connective tissue properties all decline in ways that are not captured by measuring muscle size alone.
So the popular 'X% of muscle per decade' framing gets it wrong in two directions at once. It overstates how much mass most people actually lose during most of adulthood, and it misses that the functional consequence, the loss of strength, is the bigger and faster-moving problem. A person tracking muscle mass on a body composition scan and seeing a small decline could reasonably, and wrongly, conclude they are aging well, while their functional strength has fallen considerably more.
The single most cited piece of evidence behind claims that growth hormone reverses aging is a 1990 study of human growth hormone in men over 60.4 It is worth describing exactly what that trial did, because almost none of what circulates about it describes it accurately.
The study enrolled 12 men. It ran for six months. It measured changes in lean body mass and fat mass, and it found that the men receiving growth hormone gained lean mass and lost fat mass relative to those who did not. That is the entire result. The trial did not measure strength, physical function, exercise capacity, or any outcome a person would actually feel or use in daily life. It measured body composition and nothing else.
A study of 12 men over six months, in a specific era of GH dosing that later research came to view as aggressive by modern standards, is not a basis for population-level claims about reversing aging. It is a small, short pilot study that identified an interesting body composition signal, which is exactly the kind of result that should prompt larger, longer, better-designed follow-up trials, not marketing claims. Those follow-up trials happened, and they told a more complicated story than the original headline suggested.
A systematic review of the safety and efficacy of growth hormone in the healthy elderly pulled together the trials that followed the 1990 pilot and delivered the verdict that the smaller study could not.5 It found that GH produced small changes in body composition, generally an increase in lean mass and a decrease in fat mass, broadly consistent in direction with the earlier pilot.
It also found a meaningful adverse event burden. Participants receiving GH experienced higher rates of side effects including soft tissue edema, joint pain, carpal tunnel syndrome, and glucose intolerance or new-onset diabetes, at rates the review considered clinically relevant rather than incidental.5 The review's overall framing was that the body composition benefit was modest and the safety cost was real, which is a very different conclusion than 'growth hormone reverses aging.'
That combination, small benefit plus meaningful risk, is the actual state of the evidence for growth hormone therapy in healthy older adults specifically. It is not a case against growth-hormone-axis medicine as a category; it is a specific finding about giving GH itself, at the doses studied, to healthy elderly people without a growth hormone deficiency.
A different approach tested an oral ghrelin mimetic, a compound that stimulates GH release through a different receptor pathway than GH-releasing hormone analogs, in a randomized trial in healthy older adults.6 The trial found real changes in body composition, along with measurable metabolic effects.
What it did not find was much movement on the clinical outcomes and functional measures the trial also tracked. Body composition changed in the expected direction; the things people actually care about in daily life, strength and function among them, largely did not follow.6 That is a recurring pattern across this entire literature: interventions that reliably move body composition scans do not reliably move the outcomes a person would notice.
The metabolic effects observed in that trial are also worth naming rather than glossing over, since a compound that changes glucose handling in a healthy older adult is not a free intervention, even when it produces a favorable-looking body composition result.
Put the whole picture together and the ordering is uncomfortable for a company that sells a GH-axis product, but it is the honest one. Resistance training is the intervention in this space backed by outcome data on strength and function, the exact measures that the GH and ghrelin-mimetic trials mostly failed to move. Nothing in the peptide literature reviewed here changes that ordering.
Astra prescribes compounded sermorelin, a growth-hormone-releasing hormone analog, for adults with clinical and lab evidence supporting its use. That is a real prescribing pathway with real oversight, and it is a fundamentally different proposition from either the unregulated peptide market or the aggressive GH dosing used in some of the older trials above. But offering that product does not change what the evidence says the highest-yield intervention actually is. If the goal is strength and function after 30, the best-supported answer remains resistance training, and any peptide conversation should sit downstream of that, not instead of it.
The decline is real. The specific numbers people quote about it are usually not. Getting that distinction right changes what a rational response actually looks like.
Astra Editorial, reviewing the aging and growth hormone literature
Some decline is normal, but the widely quoted 'percent per decade' figures overstate typical mass loss for most of adulthood. The more important and less discussed finding is that strength declines faster than muscle mass does.3
It enrolled 12 men over 60, ran for six months, and found changes in lean mass and fat mass. It did not measure strength, function, or exercise capacity, and it is far too small and short to support the broad anti-aging claims made in its name.4
A systematic review found small body composition improvements alongside a meaningful rate of adverse events including edema, joint pain, carpal tunnel syndrome, and glucose intolerance in healthy elderly participants given GH.5
A deconvolution study found that both age and relative adiposity independently reduce growth hormone secretory bursts. Adiposity, unlike age, is modifiable, which changes what a rational response to declining GH looks like.1
A randomized trial of an oral ghrelin mimetic in healthy older adults found body composition changes but little movement on clinical outcomes and function, alongside metabolic effects worth weighing.6
Resistance training. It is the intervention in this space with outcome data on strength and function, the measures the GH and ghrelin-mimetic trials largely failed to move.
The GH-axis decline described here is real, and compounded sermorelin, prescribed through a state-licensed US compounding pharmacy after a clinical intake and labs, is Astra's answer to it. It does not replace resistance training as the best-supported intervention for strength and function after 30. It is a reasonable addition for adults with clinical evidence supporting its use, not a substitute for the thing the outcome data actually favors.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.